ImmuPharma (IMM) News Today GBX 1.93 +0.13 (+7.12%) As of 07:02 AM Eastern Add Compare Share Share Headlines Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock IMM Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Immupharma Share Chat. Chat About IMM Shares - Stock Quote, Charts ...August 5, 2025 | lse.co.ukImmuPharma celebrates "significant milestone" for P140 platformMarch 14, 2025 | lse.co.ukImmuPharma addresses recent share price volatilityJanuary 28, 2025 | msn.comWe Think ImmuPharma (LON:IMM) Needs To Drive Business Growth CarefullyJanuary 25, 2025 | finance.yahoo.comImmuPharma PLC (25I.MU)January 18, 2025 | ca.finance.yahoo.comSMALL CAP MOVERS: ImmuPharma lifted by groundbreaking researchJanuary 10, 2025 | msn.comAIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflowsJanuary 9, 2025 | lse.co.ukImmuPharma Targets Global Partnerships at Key Biotech EventsJanuary 9, 2025 | markets.businessinsider.comImmuPharma plc (25I.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comImmupharma Share Chat (IMM)September 18, 2024 | lse.co.ukImmuPharma obtains second warrant extension with IncantheraSeptember 10, 2024 | lse.co.ukImmuPharma narrows losses in first half as expenses fallSeptember 10, 2024 | lse.co.ukT42 Iot Track. Share ChatAugust 28, 2024 | lse.co.ukGuardian Metal Resources PLC Share Price (GMET)August 7, 2024 | lse.co.uk5x Long Qqq Share ChatMay 29, 2024 | lse.co.ukHsbc Bk.24 Share ChatMay 26, 2024 | lse.co.ukInvestigational Drugs for Chronic Inflammatory Demyelinating PolyneuropathyMay 8, 2024 | msn.comLooking for top FTSE 100 value shares? Here’s one I’d buy without hesitationMay 8, 2024 | msn.comImmupharma jumps amid new IP strategy for P140 technology platformApril 2, 2024 | lse.co.ukIncanthera says first order from skincare deal doublesMarch 25, 2024 | lse.co.ukSMALL CAP MOVERS: Versarien soars as advanced materials group offloads non-core assetsMarch 15, 2024 | msn.comImmuPharma CEO Tim McCarthy discusses financial stability and promising drug developmentsMarch 8, 2024 | finance.yahoo.comImmuPharma PLC IMMFebruary 24, 2024 | morningstar.comMUK government borrowing surplus rises in January from prior yearFebruary 21, 2024 | lse.co.ukImmuPharma PLC (25I.SG)January 17, 2024 | ca.finance.yahoo.comEARNINGS AND TRADING: Time Finance revenue up; Libertine loss narrowsDecember 19, 2023 | lse.co.ukImmuPharma launches GBP2 million fund raise as interim loss narrowsAugust 31, 2023 | lse.co.ukImmuPharma to Raise up to GBP1.85 Mln to Fund R&D Pipeline, Working CapitalAugust 31, 2023 | marketwatch.comImmuPharma agrees 12 month extension to Incanthera warrant instrumentAugust 21, 2023 | lse.co.ukImmuPharma "absolutely delighted" to push on with new clinical trialJune 27, 2023 | proactiveinvestors.comImmuPharma presses on with next phase of Lupuzor clinical trialsJune 19, 2023 | proactiveinvestors.comImmuPharma "looking forward with quiet confidence" to FDA responseMay 24, 2023 | proactiveinvestors.comFTSE 100 remains higher but off best with Wall Street indicated mixedMay 18, 2023 | uk.investing.comImmuPharma Shares Rise on Positive Guidance From US FDA for P140May 18, 2023 | marketwatch.comImmuPharma shares jump 6.5% after FDA updateMay 18, 2023 | proactiveinvestors.comImmuPharma says CIDP trial will begin in the second half after meeting with US regulatorMay 18, 2023 | proactiveinvestors.comSystemic Lupus Erythematous SLE Drug Market, Global Outlook and Forecast 2023-2029May 12, 2023 | marketwatch.comImmuPharama eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma eyes clinical trial progressMay 11, 2023 | proactiveinvestors.comImmuPharma "looking forward" to upcoming FDA meetingsApril 27, 2023 | proactiveinvestors.comImmuPharma partner gets FDA meeting dateApril 19, 2023 | proactiveinvestors.comImmuPharma Shares Jump as FDA Meeting Date Set for P140 Clinical ProgramApril 12, 2023 | marketwatch.comImmuPharma rises 4% after it reveals headway with lead assetApril 12, 2023 | proactiveinvestors.comImmuPharma makes progress developing second indication for lead assetApril 12, 2023 | proactiveinvestors.comSystemic Lupus Erythematosus (SLE) Drugs Market Top Players By 2031March 30, 2023 | marketwatch.comImmuPharma: US partner has submitted Lupuzor phase II/III trial protocolMarch 27, 2023 | proactiveinvestors.comImmuPharma Shares Rise on Lupus Candidate FDA Trial SubmissionMarch 27, 2023 | marketwatch.comImmuPharma: US partner submits Lupuzor phase II/III trial protocolMarch 27, 2023 | proactiveinvestors.comImmuPharma collaborates on potential 'radioactive bullet' to kill cancerMarch 6, 2023 | proactiveinvestors.comCutaneous Lupus Erythematosus (CLE) Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsFebruary 14, 2023 | marketwatch.com Get ImmuPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMM Media Mentions By Week IMM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMM News Sentiment▼0.001.03▲Average Medical News Sentiment IMM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMM Articles This Week▼00▲IMM Articles Average Week Get the Latest News and Ratings for IMM and Related Stocks Enter your email address to receive the latest news and analysts' ratings for ImmuPharma and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies SAR News AREC News FAB News POLB News OPTI News IXI News OBD News HEMO News VAL News ONC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (LON:IMM) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access